Komori
Pharma Foods International (2929) · RiskMitigated

Business impacts of pathogens such as avian influenza

First written in FY2019. 3 of 6 entries say "Mitigated", first in FY2020-Q3. Latest entry: FY2024-Q2.

6entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseMitigatedFY2020-Q3RestatedFY20212019: 120192020: 220202021: 120212022: 020222023: 120232024: 12024
Same theme, other companies
Risk of COVID-19 impacts on business activities, supply chains, demand and financial performanceA theme 1257 companies write about · 1269 as a headwind · 6 as a tailwind

The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.

51 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 196 companies compared. The sentences above are computed from all 196.Comparing 200 of the theme's 1283 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2024-Q2MitigatedAnnual report

    「The reclassification of COVID-19 as a Class 5 disease accelerated the normalisation of economic and social activity, and the economy remained on a moderate recovery trend.」

    The disclosure states that the reclassification of COVID-19 as a Class 5 disease accelerated the normalisation of economic and social activity.
  2. FY2024-Q1MitigatedAnnual report

    「During the cumulative first quarter, Japan’s economy remained on a moderate recovery trend as economic and social activity normalised further following the reclassification of COVID-19 as a Class 5 disease under the Infectious Diseases Control Act.」

    The disclosure states that the reclassification of COVID-19 as a Class 5 disease accelerated the normalisation of economic and social activity.
  3. FY2021RestatedAnnual report

    「In response to the global COVID-19 pandemic, the group has implemented measures to prevent the spread of infection in accordance with guidelines from the government, prefectural governments and other relevant bodies. These measures include raising employees’ awareness and knowledge of occupational health and safety, as well as infection-control measures such as web conferences, staggered working hours and working from home. As of the present time, there has been no impact on business development or operating performance.」

    The group continued infection-prevention measures and stated that, as of the end of the current consolidated fiscal year, there had been no impact on business development or operating performance.
  4. FY2020-Q3MitigatedAnnual report

    「As COVID-19 spread, the call centre operated by a group subsidiary continued operations by rigorously implementing infection-prevention measures, without any infections occurring, and there was no impact on performance.」

    The disclosure states that, during the spread of COVID-19, the call centre continued operations without any infections occurring and without affecting performance by rigorously implementing infection-prevention measures.
  5. FY2020-Q2MaterialisedAnnual report

    「As the impact of COVID-19 on overseas shipments has eased, the group expects sales growth and higher profit in both its functional-materials and OEM businesses.」

    The disclosure indicates that COVID-19 had affected overseas shipments, while stating that the impact has eased.
  6. FY2019First statedAnnual report

    「If the spread of a new pathogen or similar event disrupts business operations in both sales and manufacturing, it may affect the group’s operating performance.」

    The group identifies the possibility that the spread of pathogens such as avian influenza could disrupt both sales and manufacturing as a risk.
Moved together

"Decline in Cash and Cash Equivalents" moved the same way as this thread, in the same document, in 4 of its 6 moves.

433333★123456
  1. ★This thread
  2. 1Decline in Cash and Cash Equivalents4×
  3. 2Revenue Growth and Return to Profitability in the Mail-Order Business3×
  4. 3Research and Development Expenditure3×
  5. 4Raising Working Capital through Borrowings3×
  6. 5Development of Medicated Hair Growth Product Nyumo as a New Core Product3×
  7. 6Functional Materials business: lower revenue and profit3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Pharma Foods International yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.